Table 1.
Summary of clinical efficacy at week 52
| Overall population | Anti-TNF-naïve | Anti-TNF-IR | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Secukinumab | |||||||||
| Efficacy endpoints | 300 mg | 150 mg | 150 mg no load | 300 mg | 150 mg | 150 mg no load | 300 mg | 150 mg | 150 mg no load |
| (N = 222) | (N = 220) | (N = 222) | (N = 154) | (N = 155) | (N = 158) | (N = 68) | (N = 65) | (N = 64) | |
| ACR20 response, % | 68.9 | 64.1 | 65.8 | 72.7 | 74.2 | 69.6 | 60.3 | 40.0 | 56.3 |
| ACR50 response, % | 46.8 | 41.4 | 43.2 | 53.2 | 49.7 | 48.1 | 32.4 | 21.5 | 31.3 |
| ACR70 response, % | 28.8 | 25.9 | 24.8 | 33.1 | 30.3 | 26.6 | 19.1 | 15.4 | 20.3 |
| PASI 75 response (BL psoriasis ≥3% body surface area), % | (n = 110) 74.5 | (n = 125) 63.2 | (n = 117) 59.8 | (n = 75) 77.3 | (n = 95) 69.5 | (n = 92) 63.0 | (n = 35) 68.6 | (n = 30) 43.3 | (n = 25) 48.0 |
| PASI 90 response (BL psoriasis ≥3% body surface area), % | (n = 110) 57.3 | (n = 125) 47.2 | (n = 117) 41.0 | (n = 75) 56.0 | (n = 95) 54.7 | (n = 92) 43.5 | (n = 35) 60.0 | (n = 30) 23.3 | (n = 25) 32.0 |
| HAQ-DI score, LS mean change from BL (s.e.) | −0.56 (0.04) | −0.50 (0.04) | −0.52 (0.04) | −0.59 (0.04) | −0.57 (0.04) | −0.57 (0.04) | −0.57 (0.08) | −0.40 (0.08) | −0.46 (0.08) |
| Enthesitis resolution (enthesitis subset), % | (n = 140) 70.7 | (n = 141) 63.1 | (n = 129) 61.2 | (n = 97) 76.3 | (n = 93) 69.9 | (n = 87) 64.4 | (n = 43) 58.1 | (n = 48) 50.0 | (n = 42) 54.8 |
| Dactylitis resolution (dactylitis subset), % | (n = 82) 69.5 | (n = 80) 72.5 | (n = 103) 68.9 | (n = 55) 80.0 | (n = 52) 80.8 | (n = 79) 72.2 | (n = 27) 48.1 | (n = 28) 57.1 | (n = 24) 58.3 |
Missing values were imputed as non-response for binary variables and MMRM analysis for continuous variables. BL: baseline; DAS28-CRP: 28-joint DAS using CRP; HAQ-DI: HAQ-Disability Index; LS: least squares; PASI: Psoriasis Area and Severity Index; MMRM: mixed-effect model repeated measure; N: total number of patients; n: number of patients with that symptom at baseline.